Deeptech factory

i.Ther Technology: Protein complexes combining an L1 ligand (an antibody) of a receptor selectively expressed on the surface of immune cells, with an L2 ligand of heparan sulfate proteoglycans (HSPGs).
HSPGs often act as co-receptors promoting cell signaling and potentiating receptor-mediated activation.

BB101 targets FcγRs and binds to the HSPG co-receptor. This product offers a promising strategy to remodel the myeloid compartment and slow cancer progression, either as monotherapy or in combination therapy.

BB101 has a mode of action that allows it to be active as a single agent, acting upstream of the cells targeted by immunotherapies that act on checkpoints inhibitors (anti-PDA, anti-PDL1, etc.). Thus, BB101 will be complementary to standard treatments.